BMY

Business profile & competitive position

Bristol-Myers Squibb Company is a $128.8 billion large-cap biopharmaceutical company classified under the Healthcare sector in the Drug Manufacturers - General industry. Its most recent 10-K describes it as a single-segment business engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines for serious diseases. The therapeutic focus areas are oncology, hematology, immunology, cardiovascular, and neuroscience, and products are sold worldwide mainly to wholesalers, distributors, and specialty pharmacies, with smaller sales to retailers, hospitals, clinics, government agencies, and patients.

The profitability metrics point to a high-return, capital-efficient operation. Net margin is 18.5% and return on equity is 43.9%. A net margin in the high teens is strong for a branded-drug business, but an ROE of 43.9% that is more than double the net margin indicates that leverage or a reduced equity base is amplifying shareholder returns, not operating margin alone. That profile fits a company relying on patent-protected specialty medicines with pricing power. The reinvestment rate backs the strategy: R&D spending was $10.0 billion in 2025, $11.2 billion in 2024, and $9.3 billion in 2023, and the pipeline includes over 45 unique assets in development.

Financial posture

At a current price of $63.02, BMY carries a trailing P/E of 13.9x and a market capitalization of $128.8 billion. That multiple is low relative to the company’s current profitability, suggesting the market is pricing in skepticism about how quickly new products can replace revenue lost to future patent expirations rather than questioning today’s margins.

Profitability remains intact. The 18.5% net margin and 43.9% ROE show that the existing portfolio converts sales into shareholder returns efficiently. Beta is just 0.23, meaning the stock has historically been far less volatile than the overall market, consistent with a defensive pharmaceutical cash-flow stream. Technically, the 50-day EMA is $61.73 and the RSI is 56.6, so the price sits near its short-term moving average without reaching overbought levels.

The combination of a low P/E, high ROE, and low beta can be read as a market concern about future growth, not current quality. Whether that valuation gap closes depends on pipeline and business-development execution.

Strategic priorities & outlook

Bristol-Myers Squibb’s 10-K outlines four near-term priorities: focus on transformational medicines where it has a competitive advantage, drive operational excellence, allocate capital for long-term growth and shareholder returns, and execute commercially on key first-in-class and/or best-in-class marketed products.

Revenue scale gives context for that agenda. Total revenues were $48.194 billion in 2025, nearly unchanged from $48.300 billion in 2024 and up from $45.006 billion in 2023. Geography matters: 69% of 2025 revenue came from the United States, 29% from International markets, and 2% from Other. That 69% domestic skew means U.S. pricing and reimbursement decisions will heavily influence whether the company can sustain its top line.

Business-development activity in 2025 included the acquisition of Orbital Therapeutics, a global strategic collaboration with BioNTech, and a global exclusive licensing agreement with Philochem. Those transactions fit the priority of refreshing the pipeline through external innovation while internal R&D spending stays near $10 billion annually.

Macro & geopolitical exposure

As a Drug Manufacturers - General company, BMY is exposed to the standard macro and policy risks of the global pharmaceutical industry. The most direct levers are U.S. drug-pricing legislation, Medicare and Medicaid reimbursement rules, FDA approval timelines, and the evolution of government price-setting authority. With 69% of revenue generated in the United States, any shift in federal pricing power has an outsized effect on BMY’s financials.

International exposure—29% of 2025 revenue—adds currency-translation risk and foreign reimbursement pressure. Trade policy, tariffs, and supply-chain disruptions can affect active pharmaceutical ingredient sourcing and finished-goods distribution, even though underlying demand for medicines is less cyclical than many consumer sectors. Patent law and the timing of generic or biosimilar entry remain long-term structural risks for the industry.

Recent developments

On October 29, 2026, BMY reported third-quarter 2026 EPS of $1.35 versus a consensus estimate of $1.10, a 22.7% surprise. The stock rose 1.78% the next day and showed a 0% five-day drift.

Media coverage immediately reflected the tension between near-term results and long-term risk. On October 30, 2026, Zacks highlighted “BMY Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress,” while SeekingAlpha published “Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade).” On November 2, 2026, Zacks ran “BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?” and The Motley Fool compared BMY with AbbVie in “AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?” The mix of raised guidance and a downgrade around patent-cliff concern fits a stock priced for both current cash flow and future pipeline uncertainty.

Earnings behavior & post-earnings drift

BMY has delivered an 8-for-8 beat rate over the last eight reported quarters, with an average earnings surprise of 17.4%. The beats have been sizable. In the most recent four quarters, surprises ranged from 2.4% to 27.5%. The July 30, 2026 report was the largest of the group: actual EPS of $2.04 against a $1.60 estimate, a 27.5% beat.

Yet the post-earnings price action has not rewarded the streak. The average five-day move after earnings across the last eight quarters is -2.56%, classified as a “down” drift. The recent quarter-to-quarter data show this fade clearly. After the October 29, 2026 report, the stock rose 1.78% the next day but drifted 0% over five days. After July 30, 2026, it gained 0.69% the next day and then fell 1.09% over the following five days. After April 30, 2026, an 11.3% beat still produced a -3.91% next-day drop and a -7.16% five-day decline. Only the February 5, 2026 quarter bucked the pattern: a 4.15% next-day gain and a 0.57% five-day gain.

One interpretation is that the market’s real expectation has been stronger than the published consensus, so the reported beat is already priced in by the time results arrive. The next scheduled report is February 4, 2027, before the market open, with a current consensus EPS estimate of $1.52.

For a deeper dive into how sell-side analysts are modeling BMY’s pipeline, patent cliff, and capital allocation, review the full institutional consensus and ratings verdict.